AR102767A1 - Inhibidores de ezh2 - Google Patents

Inhibidores de ezh2

Info

Publication number
AR102767A1
AR102767A1 ARP150103834A ARP150103834A AR102767A1 AR 102767 A1 AR102767 A1 AR 102767A1 AR P150103834 A ARP150103834 A AR P150103834A AR P150103834 A ARP150103834 A AR P150103834A AR 102767 A1 AR102767 A1 AR 102767A1
Authority
AR
Argentina
Prior art keywords
ezh2 inhibitors
dihydropyridin
methylthiophene
carboxamide
oxo
Prior art date
Application number
ARP150103834A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR102767A1 publication Critical patent/AR102767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque se selecciona a partir del grupo que consiste de: N-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-5-{(1R)-1-[trans-4-(3-metoxiazetidin-1-il)ciclohexil]etil}-4-metiltiofen-3-carboxamida de fórmula (1), o una sal del mismo farmacéuticamente aceptable, y N-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-5-{(1S)-1-[trans-4-(3-metoxiazetin-1-il)ciclohexil]etil}-4-metiltiofen-3-carboxamida de fórmula (2), o una sal del mismo farmacéuticamente aceptable.
ARP150103834A 2014-12-05 2015-11-24 Inhibidores de ezh2 AR102767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088045P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
AR102767A1 true AR102767A1 (es) 2017-03-22

Family

ID=55025363

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103834A AR102767A1 (es) 2014-12-05 2015-11-24 Inhibidores de ezh2

Country Status (4)

Country Link
US (1) US9527837B2 (es)
AR (1) AR102767A1 (es)
TW (1) TW201636344A (es)
WO (1) WO2016089804A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2018135556A1 (ja) 2017-01-19 2018-07-26 第一三共株式会社 Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
MX2020007974A (es) 2018-01-31 2020-09-07 Mirati Therapeutics Inc Inhibidores de complejo represivo polycomb 2 (prc2).
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
US20220257577A1 (en) * 2019-07-24 2022-08-18 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521794A (ja) 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
SG185431A1 (en) 2010-05-07 2012-12-28 Glaxosmithkline Llc Indoles
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2836491B1 (en) 2012-04-13 2016-12-07 Epizyme, Inc. Salt form of a human histone methyltransferase ezh2 inhibitor
AU2013245661B2 (en) 2012-04-13 2017-11-23 Epizyme, Inc. Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
JP2016503009A (ja) 2012-12-13 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
KR20160003115A (ko) 2013-04-30 2016-01-08 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
CN113289022A (zh) 2014-06-17 2021-08-24 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂

Also Published As

Publication number Publication date
US20160159782A1 (en) 2016-06-09
WO2016089804A1 (en) 2016-06-09
US9527837B2 (en) 2016-12-27
TW201636344A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
AR102767A1 (es) Inhibidores de ezh2
EA201790398A1 (ru) Способы лечения заболевания печени
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
AR103680A1 (es) Inhibidores selectivos de bace1
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2017002670A (es) Inhibidores de glucosidasa.
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
EA201692480A1 (ru) Фармацевтическая композиция
BR112014028042A2 (pt) inibidores de nampt
EA201891342A1 (ru) Изоиндольные соединения
MY194106A (en) Dihydroindolizinone derivative
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
AR104342A1 (es) Compuesto heterocíclico
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
SV2016005313A (es) Derivados de carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
JOP20190163B1 (ar) منشط nrf2

Legal Events

Date Code Title Description
FB Suspension of granting procedure